The FDA entry shows that the lidocaine ointment 5% received agency approval on the 25 September 2017. The drug is an anaesthetic to be used on serious cuts or lesions, for both emergency and home use. It is a prescription-only product.

Vitruvias developed the drug with Sunny Pharmtech, a Taiwan-based active pharmaceutical ingredient (API) and drugmaker.

This is the first generic drug approval for both companies and is part of a joint development agreement that the companies say now includes eight products. The joint application was filed in November 2016. It received first-cycle approval after a 10-month review, a feat that only 9% of this type of application manages to achieve.

The drug is expected to be on the market by the end of 2017 and will be manufactured by Canada-based Halo Pharma.

Related articles
FDA lists drugs without generics to increase competition

FDA approval for generics of ADHD drug Strattera

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2017 Pro Pharma Communications International. All Rights Reserved.